Industry groups BIO and PhRMA gave Turing Pharmaceuticals and its CEO, Martin Shkreli, the cold shoulder.
.@TuringPharma does not represent the values of @PhRMA member companies.
— PhRMA (@PhRMA) September 22, 2015
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
BIO kicked Turing out of the group.
Shkreli, in about as plain of terms as you could get, does not care. Here’s what he had to say (starts at 17:31 mark) Friday on MedHeads, MedCityNews.com’s weekly video podcast.
PhRMA, BIO – I think they’re all hypocrites.
I didn’t even know we were part of BIO. It’s one of the most sycophantic self-serving groups there is. I don’t know what value they provide. They begged us to be a member for years.
They said something like we don’t fulfill the objective of BIO in doing research? We spend more money in research than I would venture to guess more than 75 percent of BIO members. That’s sort of bullshit to me.
PhRMA? Again, talk about an industry that relies on price increases for growth? You’re looking at it.
So why the cold shoulder from the industry? “Perhaps there’s criticism because I’m 32-years-old, I don’t wear a suit, the average guy with my job is double my age, looks a little bit differently,” he said.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
